FGF23 adds value to risk prediction in patients with chronic kidney disease

Bone

Volumn 51, Issue 4, 2012, Pages 830-831

  Smith, Edward R ^a,d   Ford, Martin L ^a,b   Tomlinson, Laurie A ^c   McMahon, Lawrence P ^d   Rajkumar, Chakravarthi ^b   Holt, Stephen G ^a,d  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; LETTER; PREDICTION; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84865622370     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.05.017     Document Type: Letter

References (13)

1. Nakano C., Hamano T., Fujii N., Obi Y., Matsui I., Tomida K., et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012, 10.1016/j.bone.2012.02.634.
2. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
3. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
4. Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
5. Ford M.L., Smith E.R., Tomlinson L.A., Chatterjee P.K., Rajkumar C., Holt S.G. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012, 27:727-733.
6. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. (discussion 207-12).
7. Steyerberg E.W., Vickers A.J., Cook N.R., Gerds T., Gonen M., Obuchowski N., et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010, 21:128-138.
8. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
9. Nakano C., Hamano T., Fujii N., Matsui I., Tomida K., Mikami S., et al. Combined Use of Vitamin D Status and FGF23 for Risk Stratification of Renal Outcome. Clin J Am Soc Nephrol 2012, 10.2215/CJN.08680811.
10. Smith E.R., Ford M.L., Tomlinson L.A., Weaving G., Rocks B.F., Rajkumar C., et al. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta 2011, 412:1008-1011.
11. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
12. Bacchetta J., Cochat P., Salusky I.B., Wesseling-Perry K. Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol 2012, 10.1007/s00467-012-2110-3.
13. Imel E.A., Peacock M., Pitukcheewanont P., Heller H.J., Ward L.M., Shulman D., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91:2055-2061.